Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Last trade$27.82
Day change-$0.11 (-0.39%)
Day range$27.08 – $28.24
Volume203,061
Market cap$1.89B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.89B
Price / earnings
—
Price / book
7.67×
Price / sales
1,894.15×
EV / sales
1,994.59×
EV / EBITDA
-4.19×
Profitability
Earnings per share
-$7.14
Return on assets
-69.03%
Return on equity
-196.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.2×
Current ratio
9.93×
Quick ratio
9.93×
Cash ratio
2.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$225.97M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZBIO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$1M
$0
$0
$0
$0
$10M
$5M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1M
$0
$0
$0
$0
$10M
$5M
$0
Selling, general and administrative
$15.75M
$16.91M
$15.59M
$13.18M
$12.14M
$12.42M
$11.47M
$7.45M
Research and development
$92.91M
$60.44M
$222.39M
$39.4M
$43.03M
$34.92M
$49.16M
$33.53M
Total operating expenses
$108.66M
$77.35M
$237.98M
$52.58M
$55.16M
$47.33M
$60.62M
$40.98M
Operating income
-$107.66M
-$77.35M
-$237.98M
-$52.58M
-$55.16M
-$37.33M
-$55.62M
-$40.98M
Interest expense
-$8.56M
-$368K
-$7.33M
$0
$0
$0
$0
$0
Income before taxes
-$111.34M
-$80.99M
-$240.34M
-$51.5M
-$52.2M
-$33.78M
-$52.18M
-$38.61M
Income taxes
$114K
$0
$106K
$0
$20K
-$205K
$429K
$0
Net income
-$111.46M
-$80.99M
-$240.44M
-$51.5M
-$52.22M
-$33.57M
-$52.6M
-$38.61M
Net income attributable to common shareholders
-$111.46M
-$80.99M
-$240.44M
-$51.5M
-$52.22M
-$33.57M
-$52.6M
-$38.61M
EBITDA
-$107.66M
-$77.34M
-$237.97M
-$52.57M
-$55.15M
-$37.31M
-$55.59M
-$40.95M
Basic earnings per share
-$1.77
-$1.46
-$4.53
-$1.22
-$1.25
-$0.80
-$1.25
-$5.02
Diluted earnings per share
-$1.77
-$1.46
-$4.53
-$1.22
-$1.25
-$0.80
-$1.25
-$5.02
Recent news
Company coverage with links to the original publishers.
Zenas BioPharma (ZBIO) has gained 2.7% over the past four weeks and closed at $28.23. Wall Street analysts have set a mean price target of $50.14, indicating a potential 77.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.
Zenas BioPharma announced on September 15, 2026, that its Compensation Committee granted inducement stock options to purchase 53,700 shares and 98,900 restricted stock units to newly hired employees. The stock options have a 10-year term with an exercise price of $31.93 per share and vest over four years, while RSUs vest equally over four years through 2030.
Zenas BioPharma announced that obexelimab met its primary and all key secondary endpoints in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The drug demonstrated a 56% reduction in flare risk, 65% reduction in glucocorticoid use, and favorable safety profile comparable to placebo. A Biologics License Application (BLA) was submitted to the FDA in May 2026, with results presented at EULAR 2026 Congress and published in the New England Journal of Medicine.
Zenas BioPharma reported Q1 2026 financial results with cash position of $718.5M and extended runway through Q2 2029. The company advanced obexelimab toward FDA/EMA submissions for IgG4-RD treatment, completed enrollment in the Phase 2 SunStone SLE trial with results expected Q4 2026, initiated Phase 1 testing of oral IL-17 inhibitor ZB021, and continued Phase 3 trials for orelabrutinib in multiple sclerosis. R&D expenses increased to $60.4M from $34.9M year-over-year, and net loss widened to $81.0M from $33.6M, primarily due to increased clinical trial and manufacturing costs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 24, 2019
$0.002
Jan 2, 2020
recurring
Sep 25, 2019
$0.0171
Oct 2, 2019
recurring
Jun 25, 2019
$0.0155
Jul 2, 2019
recurring
Mar 20, 2019
$0.0133
Mar 27, 2019
recurring
Dec 26, 2018
$0.005
Jan 3, 2019
recurring
Stock splits
Historical share-structure events and their execution dates.